LIVENT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.862 USD | -8.53% |
|
+0.00% | -8.18% |
| Apr. 09 | KeyBanc Trims Price Target on Arcadium Lithium to $11 From $12, Keeps Overweight Rating | MT |
| Apr. 04 | Raymond James Upgrades Arcadium Lithium to Strong Buy from Outperform | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 12.93 for the current year and 6.25 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.18% | 4.09B | B+ | ||
| +9.99% | 62.67B | A- | ||
| -6.50% | 45.97B | A- | ||
| +13.40% | 39.51B | B+ | ||
| +17.90% | 26.04B | A- | ||
| +1.03% | 17.71B | C+ | ||
| -0.59% | 17.25B | B+ | ||
| +5.78% | 15.44B | B+ | ||
| -29.39% | 14.54B | A- | ||
| -22.38% | 13.14B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALTM Stock
- LTHM Stock
- Ratings LIVENT
